Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chu, Chih Sheng ^a,b,c   Wang, Yu Chen ^d,e   Lu, Long Sheng ^d,f   Walton, Brian ^d   Yilmaz, H Ramazan ^d,g   Huang, Roger Y ^d   Sawamura, Tatsuya ^h   Dixon, Richard A F ^d   Lai, Wen Ter ^a   Chen, Chu Huang ^c,d,e,i   Lu, Jonathan ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS HEART INSTITUTE   (United States)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^g MEVLANA UNIVERSITY   (Turkey)

^h NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; UPREGULATION; VASCULAR ENDOTHELIUM;

ADULT; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRROLES; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS E;

EID: 84881345898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070533     Document Type: Article

References (51)

1. Ross R, (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126.
2. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB, (1994) The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest 94: 1390-1396.
3. Vigushin DM, Pepys MB, Hawkins PN, (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351-1357.
4. De Servi S, Mariani M, Mariani G, Mazzone A, (2005) C-reactive protein increase in unstable coronary disease cause or effect? J Am Coll Cardiol 46: 1496-1502.
5. Ridker PM, (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369.
6. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, et al. (2003) Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108: 512-515.
7. Devaraj S, Venugopal S, Jialal I, (2006) Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 184: 48-52.
8. Libby P, Ridker PM, (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116Suppl 6A: 9S-16S.
9. Ferri C, Croce G, Cofini V, De Berardinis G, Grassi D, et al. (2007) C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Curr Pharm Des 13: 1631-1645.
10. Venugopal SK, Devaraj S, Jialal I, (2005) Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 166: 1265-1271.
11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
12. Castelli WP, Anderson K, Wilson PW, Levy D, (1992) Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2: 23-28.
13. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D, (1994) Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15: 1300-1331.
14. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, et al. (2003) Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107: 2102-2108.
15. Avogaro P, Bon GB, Cazzolato G, (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8: 79-87.
16. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, et al. (2008) Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 49: 33-47.
17. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, et al. (2008) Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 57: 158-166.
18. Lu J, Yang JH, Burns AR, Chen HH, Tang D, et al. (2009) Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 104: 619-627.
19. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, et al. (2003) Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol 23: 1083-1090.
20. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, et al. (2013) Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res [E-pub ahead of print April 15, 2013].
21. Tsai MH, Chang CL, Yu YS, Lin TY, Chong CP, et al. (2012) Chemical analysis of C-reactive protein synthesized by human aortic endothelial cells under oxidative stress. Anal Chem 84: 9646-9654.
22. Shih HH, Zhang S, Cao W, Hahn A, Wang J, et al. (2009) CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol 296: H1643-1650.
23. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, et al. (1997) An endothelial receptor for oxidized low-density lipoprotein. Nature 386: 73-77.
24. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G, (2006) Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69: 36-45.
25. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, et al. (1999) Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117.
26. Hofnagel O, Luechtenborg B, Eschert H, Weissen-Plenz G, Severs NJ, et al. (2006) Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol 26: 604-610.
27. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
28. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28.
29. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158.
30. Kobayashi K, Watanabe J, Umeda F, Nawata H, (1995) Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 42: 461-465.
31. Li L, Roumeliotis N, Sawamura T, Renier G, (2004) C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 95: 877-883.
32. Durrington P, (2003) Dyslipidaemia. Lancet 362: 717-731.
33. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, et al. (2010) Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol 47Suppl 1: 161-168.
34. Jackson RL, Morrisett JD, Gotto AM Jr, (1976) Lipoprotein structure and metabolism. Physiol Rev 56: 259-316.
35. Chen CH, Jiang W, Via DP, Luo S, Li TR, et al. (2000) Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 101: 171-177.
36. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, et al. (2001) Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation 104: 588-593.
37. Frankel DJ, Pfeiffer JR, Surviladze Z, Johnson AE, Oliver JM, et al. (2006) Revealing the topography of cellular membrane domains by combined atomic force microscopy/fluorescence imaging. Biophys J 90: 2404-2413.
38. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW, (1981) Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy. Arteriosclerosis 1: 177-185.
39. Pepys MB, Hirschfield GM, (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812.
40. Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, et al. (2011) CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J Lipid Res 52: 923-933.
41. Bang R, Marnell L, Mold C, Stein MP, Clos KT, et al. (2005) Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis. J Biol Chem 280: 25095-25102.
42. Devaraj S, Du Clos TW, Jialal I, (2005) Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 25: 1359-1363.
43. Grad E, Pachino RM, Danenberg HD, (2011) Endothelial C-reactive protein increases platelet adhesion under flow conditions. Am J Physiol Heart Circ Physiol 301: H730-736.
44. Pasceri V, Cheng JS, Willerson JT, Yeh ET, (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534.
45. Pasceri V, Willerson JT, Yeh ET, (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168.
46. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, et al. (2004) High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109: 2116-2122.
47. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, et al. (2004) Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109: 790-796.
48. Libby P, Aikawa M, (2003) Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 26: I11-14.
49. Ray KK, Cannon CP, (2004) Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 15: 637-643.
50. Ray KK, Cannon CP, (2004) Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 18: 89-101.
51. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.